Abstract
The article entitled “Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate”, by Lu D.Y., Lu T.R., Xu B., Varki A., Huang M., Zhu H., Shen Y., Yarla N.S., has been retracted on the request of the co-authors Dr. Ajit Varki, Ming Huang, Hong Zhu and Ying Shen available at: Anticancer Agents Med Chem. 2018; 18(14): 1952-1961. http://www.eurekaselect.com/165282.
The Corresponding Author Dr. Da-Yong Lu has included the name of the co-author Dr. Ajit Varki, Dr. Nagendra Yarla, Ming Huang, Hong Zhu and Ying Shen without their consent and the manuscript has been published in the journal Anti-Cancer Agents in Medicinal Chemistry (ACAMC). Kindly see Bentham Science Policy on Article retraction at the link given below:
https://benthamscience.com/journals/anti-cancer-agents-in-medicinal-chemistry/editorial-policies/).
Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.
Anti-Cancer Agents in Medicinal Chemistry
Title:RETRACTED: Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate
Volume: 18 Issue: 14
Author(s): D.Y. Lu, T.R. Lu and B Xu
Affiliation:
Abstract: The article entitled “Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate”, by Lu D.Y., Lu T.R., Xu B., Varki A., Huang M., Zhu H., Shen Y., Yarla N.S., has been retracted on the request of the co-authors Dr. Ajit Varki, Ming Huang, Hong Zhu and Ying Shen available at: Anticancer Agents Med Chem. 2018; 18(14): 1952-1961. http://www.eurekaselect.com/165282.
The Corresponding Author Dr. Da-Yong Lu has included the name of the co-author Dr. Ajit Varki, Dr. Nagendra Yarla, Ming Huang, Hong Zhu and Ying Shen without their consent and the manuscript has been published in the journal Anti-Cancer Agents in Medicinal Chemistry (ACAMC). Kindly see Bentham Science Policy on Article retraction at the link given below:
https://benthamscience.com/journals/anti-cancer-agents-in-medicinal-chemistry/editorial-policies/).
Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.
Export Options
About this article
Cite this article as:
Lu D.Y., Lu T.R. and Xu B, RETRACTED: Aberrant Sialylation in Cancer Pathology and Metastasis, a Putative Drug Target Candidate, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (14) . https://dx.doi.org/10.2174/1871520618666180911113141
DOI https://dx.doi.org/10.2174/1871520618666180911113141 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: The Importance of Case Reports and Case Series in Helping Diagnose Rare Diseases
Current Respiratory Medicine Reviews Intracellular Signaling Pathways Modulated by Phenolic Compounds: Application for New Anti-Inflammatory Drugs Discovery
Current Medicinal Chemistry Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets
Current Pharmaceutical Design INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Cytokinin Nucleosides - Natural Compounds with a Unique Spectrum of Biological Activities
Current Topics in Medicinal Chemistry Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine
Current Drug Targets Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry FAK and p53 Protein Interactions
Anti-Cancer Agents in Medicinal Chemistry Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology